Results 131 to 140 of about 2,379 (179)

Non-tuberculous mycobacterial infection in cystic fibrosis before and after initiation of elexacaftor/tezacaftor/ivacaftor: now is not the time to lower the guard. [PDF]

BMJ Open Respir Res
Evans IES, Smith D, Henderson D, Riddles T, Masel P, Moore V, Burke AJ, Thomson RM, Reid DW.   +8 more
europepmc   +1 more source

Impact of Elexacaftor-Tezacaftor-Ivacaftor on Muscle Composition in Cystic Fibrosis: An AI-Assisted Chest CT-Based Body Composition Analysis. [PDF]

Med Sci (Basel)
Welsner M, Stehling F, Gruber W, Westhölter D, Sutharsan S, Taube C, Büscher E, Nensa F, Zensen S, Umutlu L, Forsting M, Haubold J, Salhöfer L, Holtkamp M, Kohnke J, Hosch R, Opitz M.   +16 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Use of elexacaftor/tezacaftor/ivacaftor combination in pregnancy

Archives of Gynecology and Obstetrics, 2023
Management of cystic fibrosis has recently stepped forward with the introduction of cystic fibrosis transmembrane conductance regulator (CFTR) modulators, although data on potential adverse effects are lacking for many categories of patients, such as pregnant women.We report one of the first reports on the outcome of pregnancy in a woman treated with ...
Giuseppe Cimino, Sara Sorrenti, Manuel Murciano, Paola Galoppi, Fiorentina Ascenzioni, Bruno Botta, Roberto Brunelli, Luca Cavinato, Andrea Cerrato, Gabriele Cianfoni, Valentina D’Ambrosio, Francesca De Luca, Paola Delporto, Maria Di Chiara, Paola Galoppi, Francesco Gasparrini, Francesca Ghirga, Antonella Giancotti, Aldo Laganà, Giulia Mazzoccanti, Alessandro Mondo, Carmela Maria Montone, Manuel Murciano, Francesco Pecorini, Maria Grazia Piccioni, Damiana Pompeo, Lorenzo Spiniello, Gianluca Terrin, Patrizia Troiani, Fabrizio Zullo   +29 more
openaire   +3 more sources

Elexacaftor/Tezacaftor/Ivacaftor Treatment and Depression-related Events

American Journal of Respiratory and Critical Care Medicine
Abstract Rationale Elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA) has been shown to be safe and efficacious in people with cystic fibrosis (pwCF) aged 2 years and older with at least one F508del-CFTR allele or more. After U.S.
Bonnie Ramsey, Marcus Mall, Edward Mckone   +2 more
exaly   +3 more sources

Elexacaftor-Tezacaftor-Ivacaftor and Ivacaftor (Trikafta)

Canadian Journal of Health Technologies, 2022
What Is the CADTH Reimbursement Recommendation for Trikafta? CADTH recommends that Trikafta be reimbursed by public drug plans for the treatment of cystic fibrosis (CF) in patients aged 2 to 5 years and older who have at least one F508del mutation in the CFTR gene, if certain conditions are met.
openaire   +1 more source

Management of neuropsychiatric symptoms in adults treated with elexacaftor/tezacaftor/ivacaftor

Pediatric Pulmonology, 2023
AbstractIntroductionReports of neuropsychiatric symptoms proximal to cystic fibrosis transmembrane conductance regulator (CFTR) modulator initiation are emerging, but their prevalence and management remain poorly characterized.MethodsRetrospective chart review was used to categorize symptom trajectories of all adults at a single CF Center who initiated
Evelyne Baroud, Nivedita Chaudhary, Anna M. Georgiopoulos   +2 more
openaire   +2 more sources

Mental status changes during elexacaftor/tezacaftor / ivacaftor therapy

Journal of Cystic Fibrosis, 2022
Elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA, Trikafta) is the newest Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) modulator drug approved by the Food and Drug Administration. Post-marketing reports with earlier CFTR modulators suggest these medications can impact mood, and in clinical trials an adverse effect of headache was reported ...
Suyeon Heo, David C. Young, Julie Safirstein, Brian Bourque, Martine H. Antell, Stefanie Diloreto, Shannon M. Rotolo   +6 more
openaire   +2 more sources

Elexacaftor/tezacaftor/ivacaftor treatment reduces airway inflammation in cystic fibrosis

Pediatric Pulmonology, 2022
ETI treatment reduces inflammatory markers and positive bacterial cultures on BAL in PwCF. These findings suggest that ETI has a greater impact on chronic infection and inflammation than ivacaftor alone. However, airway inflammation persists in a fraction of treated individuals, indicating an ongoing need to optimize other treatments in a subset of ...
Richard C. De Vuyst, Erin Bennard, Charissa W. Kam, Cameron J. McKinzie, Charles R. Esther   +4 more
openaire   +2 more sources

Improving Pancreatic Function With Elexacaftor/Tezacaftor/Ivacaftor

Pediatric Pulmonology
ABSTRACT Background Due to the dysfunction and destruction of pancreatic cells in individuals with cystic fibrosis (CF), most require lifelong exogenous pancreatic enzyme supplementation. The objective of this study was to determine if elexacaftor/tezacaftor/ivacaftor (ETI) treatment improves ...
Madison Pranske, Alizay Paracha, Carson Loncarich, Amy D. Hendrix‐Dicken, Joseph Walter, Michelle Condren   +5 more
openaire   +1 more source

Elexacaftor-Tezacaftor-Ivacaftor and Ivacaftor (Trikafta)

Canadian Journal of Health Technologies
Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the ...
openaire   +1 more source